NeuroRx® Changes Name to Neurotherapeutics
Publication provides critical reviews in therapy of neurological disorders
Philadelphia, 04 January 2007 - NeuroRx®, the official journal of the American Society for Experimental NeuroTherapeutics (ASENT), published by Elsevier, will be changing its name to Neurotherapeutics as of the January 2007 issue. Elsevier, the Editor-in-Chief and Editorial Board for NeuroRx® and the ASENT Board members worked closely together in 2006 to develop a new name to reinforce the true focus of the journal.
Neurotherapeutics is a unique publication providing critical reviews on selected topics in therapy of neurological disorders. Each quarterly issue focuses on dedicated topic(s), with internationally recognized authorities sharing their in-depth understanding. Neurotherapeutics offers a multidisciplinary perspective on high-profile topics in neurotherapeutics, taking in not just the scientific issues but also their social and ethical ramifications.
"Neurotherapeutics more clearly reflects the intended meaning of the journal title and positions it more accurately in the field," said Editor-in-Chief, Alan I. Faden, MD.
Citations for prior issues of the journal, which is indexed by PubMed Central and MEDLINE, will be available under both NeuroRx® and Neurotherapeutics.
# # #
The purpose of the American Society for Experimental NeuroTherapeutics is to provide a forum for broadly defined interest areas of academia, government, industry and advocacy concerned with the field of neurotherapeutics; to promote dialogue, understanding and cooperation among the interested groups; to develop information and seek consensus on matters germane to the organization’s mission; and to organize education and training for healthcare practitioners, biomedical scientists and officials participating in the neurotherapeutics field. Visit the Society's website at www.asent.org.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com